<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050163</url>
  </required_header>
  <id_info>
    <org_study_id>csho19052112001</org_study_id>
    <nct_id>NCT04050163</nct_id>
  </id_info>
  <brief_title>MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)</brief_title>
  <acronym>MiSaver®</acronym>
  <official_title>Safety and Preliminary Efficacy Study of Intravenous Administration of MiSaver® (Myocardial Infarction Saver) After Acute Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Honya Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Honya Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to establish the safety and efficacy of MiSaver® Stem
      Cell Treatment After a Heart Attack (Acute Myocardial Infarction)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose escalating</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single/participant blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricle stroke volume</measure>
    <time_frame>12 months</time_frame>
    <description>Echocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End diastolic volume</measure>
    <time_frame>12 months</time_frame>
    <description>Echocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (cc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
    <description>Calculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Physical Activity</measure>
    <time_frame>12 months</time_frame>
    <description>The Karnofsky Performance Scale Index allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the Karnofsky score, the worse the survival for most serious illnesses.
Scale ranges 0~100 (higer score better ), 100 Normal no complaints, 90 Able to carry on normal activity, 80 Normal activity with effort, 70 Cares for self but unable to carry on normal activity, 60 Requires occasional assistance, but is able to care for most of his personal needs, 50 Requires considerable assistance and frequent medical care, 40 Disabled and requires special care and assistance, 30 Severely disabled and hospital admission is indicated, 20 Very sick and hospital admission necessary, 10 Requires institutional or hospital care, 0 No life sign.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MiSaver®</intervention_name>
    <description>Intravenous administration of MiSaver® Stem Cell via peripheral vein access.</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Intermediate Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <other_name>stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 20~80

          -  Acute Myocardial Infarction 1 to 10 days

          -  Cardiac enzyme CK-MB or Troponin &gt; 2X of high-end normal value

          -  ST-elevation on EKG (STEMI)

          -  Presence of regional wall motion abnormality

          -  Left ventricular ejection fraction (LVEF) of ≤40%

          -  Hemodynamically stable past 24 hour

          -  Participants with adequate pulmonary function

          -  Peripheral artery oxygen saturation ≥97%

          -  Karnofsky performance status scores of ≥60.

        Exclusion Criteria:

          -  Age &lt;20 or &gt;80

          -  Pregnant or breast feeding

          -  Positive adventitious infections (such as HIV, hepatitis )

          -  Revascularization via coronary artery bypass surgery is required

          -  Coronary revascularization procedures is anticipated during the 6-month study period

          -  Severe aortic or mitral valve narrowing

          -  Evidence of life-threatening arrhythmia on baseline electrocardiogram (ECG)

          -  Short of breath unable to receive PCI examination or treatment

          -  Malignant tumor

          -  Hematopoietic dysplasia

          -  Severe organ disease

          -  With less than 1 year of life expectancy

          -  Chronic kidney disease with CCr&lt;20ml/min

          -  Kidney disease on renal dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jackson Liu, MD</last_name>
    <phone>+886921167980</phone>
    <email>honyamedical@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Taichung City</state>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GC Ueng, MD</last_name>
      <phone>+886424739595</phone>
      <phone_ext>34116</phone_ext>
    </contact>
    <investigator>
      <last_name>GC Ueng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HONYA Medical Inc</name>
      <address>
        <city>Tainan</city>
        <zip>74147</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackson TK Liu, MD</last_name>
      <phone>+88665055006</phone>
      <email>info@honyamedical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Attack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

